• Roche is initiating TARBELA-AD, a Phase II trial testing oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease, targeting neuroinflammation.
• Updated trontinemab results showing rapid amyloid removal and biomarker changes will be presented at CTAD in Boston, November 16-19, 2026.
• Phase III PrevenTRON has begun enrolling cognitively unimpaired participants with Alzheimer's biomarkers; its design will be presented November 18.
• Upcoming diagnostic presentations will cover clinical and economic evidence supporting Elecsys pTau217 and pTau181 blood tests for earlier Alzheimer's diagnosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202611100100BIZWIRE_USPR_____20261109_BW725756) on November 10, 2026, and is solely responsible for the information contained therein.